ReviewBritish medical bulletin2016
Heart failure-potential new targets for therapy.
Review in British medical bulletin, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Advances in the study of exosomes in cardiovascular diseases.Journal of advanced research · 2024Pooled it
- Assessment of clinical data on urocortins and their therapeutic potential in cardiovascular diseases: A systematic review and meta-analysis.Clinical and translational science · 2021Pooled it
- Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis.Heart (British Cardiac Society) · 2018Pooled it
- Relationship between enteral nutrition and serum levels of inflammatory factors and cardiac function in elderly patients with heart failure.Clinical interventions in aging · 2018Trial
- Potential Biomarker and Therapeutic Tools for Pathological Cardiac Hypertrophy and Heart Failure: Extracellular Vesicles.International journal of molecular sciences · 2025Review
- Ginsenoside Rb2 improves heart failure by down-regulating miR-216a-5p to promote autophagy and inhibit apoptosis and oxidative stress.Journal of applied biomedicine · 2023Article
- Targeting regulatory T cells for cardiovascular diseases.Frontiers in immunology · 2023Review
- Cardiac Sodium/Hydrogen Exchanger (NHE11) as a Novel Potential Target for SGLT2i in Heart Failure: A Preliminary Study.Pharmaceutics · 2022Article
- Pharmacological Targets in Chronic Heart Failure with Reduced Ejection Fraction.Life (Basel, Switzerland) · 2022Review
- Cardiac protection induced by urocortin-2 enables the regulation of apoptosis and fibrosis after ischemia and reperfusion involving miR-29a modulation.Molecular therapy. Nucleic acids · 2022Article
- Review
- Phosphorylation in Novel Mitochondrial Creatine Kinase Tyrosine Residues Render Cardioprotection against Hypoxia/Reoxygenation Injury.Journal of lipid and atherosclerosis · 2021Article
- Knock-out of MicroRNA 145 impairs cardiac fibroblast function and wound healing post-myocardial infarction.Journal of cellular and molecular medicine · 2020Article
- Beneficial effects of paricalcitol on cardiac dysfunction and remodelling in a model of established heart failure.British journal of pharmacology · 2020Article
- Re-evaluating the causes and consequences of non-resolving inflammation in chronic cardiovascular disease.Heart failure reviews · 2020Review
- Qishen granules exerts cardioprotective effects on rats with heart failure via regulating fatty acid and glucose metabolism.Chinese medicine · 2020Article
- Perindopril Improves Cardiac Function by Enhancing the Expression of SIRT3 and PGC-1α in a Rat Model of Isoproterenol-Induced Cardiomyopathy.Frontiers in pharmacology · 2020Article
- Repurposing an anti-cancer agent for the treatment of hypertrophic heart disease.The Journal of pathology · 2019Article
- Cardiac sympathetic afferent reflex control of cardiac function in normal and chronic heart failure states.The Journal of physiology · 2017Article
- Regulation of microvascularization in heart failure - an endothelial cell, non-coding RNAs and exosome liaison.Non-coding RNA research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
INTRODUCTION/
backgroundHeart failure is a major cause of cardiovascular morbidity and mortality. This review covers current heart failure treatment guidelines, emerging therapies that are undergoing clinical trial, and potential new therapeutic targets arising from basic science advances. SOURCES OF DATA: A non-systematic search of MEDLINE was carried out. International guidelines and relevant reviews were searched for additional articles. AREAS OF AGREEMENT: Angiotensin-converting enzyme inhibitors and beta-blockers are first line treatments for chronic heart failure with reduced left ventricular function. AREAS OF CONTROVERSY: Treatment strategies to improve mortality in heart failure with preserved left ventricular function are unclear. GROWING POINTS: Many novel therapies are being tested for clinical efficacy in heart failure, including those that target natriuretic peptides and myosin activators. A large number of completely novel targets are also emerging from laboratory-based research. Better understanding of pathophysiological mechanisms driving heart failure in different settings (e.g. hypertension, post-myocardial infarction, metabolic dysfunction) may allow for targeted therapies. AREAS TIMELY FOR DEVELOPING RESEARCH: Therapeutic targets directed towards modifying the extracellular environment, angiogenesis, cell viability, contractile function and microRNA-based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.